{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:00:17Z","timestamp":1790697617486,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,15]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Consolidation immunotherapy postchemoradiotherapy is standard for unresectable stage III non-small-cell lung cancer (NSCLC) per PACIFIC and GEMSTONE-301, but optimal integration with chemoradiotherapy is unclear, especially for large tumours. Induction immunotherapy before concurrent chemoradiotherapy (cCRT) may enhance tumour downstaging and immune synergy, while adaptive radiotherapy with strict lung constraints (V20 \u226420%) could reduce toxicity. This trial aims to evaluate the efficacy and safety of sintilimab with induction chemotherapy followed by adaptive radiotherapy and consolidation sintilimab in patients with unresectable stage III NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This prospective, multicentre, single-arm phase II trial will enrol 35 patients with histologically or cytologically confirmed unresectable stage III NSCLC, without sensitising mutations, and Eastern Cooperative Oncology Group(ECOG) performance status 0\u20131. Patients will receive two cycles of induction sintilimab (200\u2009mg, day 1, every 3 weeks) plus platinum-based doublet chemotherapy, followed by definitive cCRT with adaptive radiotherapy planning strictly limiting both lung V20 \u226420%. Radiotherapy dose can be delivered in three optional regimens based on tumour volume and distribution: (1) planning gross tumour volume (PGTV) 60\u201366\u2009Gy\/2.0\u20132.2 Gy\/30F with planning target volume (PTV) 54\u2009Gy\/1.8\u2009Gy\/30F; (2) PGTV 54\u201366\u2009Gy\/2.0\u20132.2 Gy\/30F without PTV irradiation or (3) PGTV 50\u2009Gy\/2.0\u2009Gy\/25F without PTV irradiation. During radiotherapy, patients will receive two additional cycles of sintilimab plus chemotherapy. Consolidation sintilimab will continue for up to 1 year or until disease progression\/unacceptable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Institutional Ethics Committee of The Third Xiangya Hospital, Central South University (approval number: R25063; the approval letter is provided as online supplemental file 1). The study results will be disseminated through publication in peer-reviewed journals, presentations at national and international scientific conferences and communication to participants and the public via institutional channels and patient advocacy groups. Individual participant data will be available on reasonable request after study completion, subject to institutional and ethical approvals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07138755\">NCT07138755<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-120335","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:24Z","timestamp":1790694084000},"page":"e120335","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Single-arm, multicentre phase II trial of sintilimab plus platinum-based doublet chemotherapy followed by adaptive radiotherapy strategy for patients with unresectable stage III non-small-cell lung cancer in China: the ART-LUNG 01 study protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07138755","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07138755","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1869-3853","authenticated-orcid":false,"given":"Li","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-0725","authenticated-orcid":false,"given":"Zewen","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1806-5308","authenticated-orcid":false,"given":"Xuewen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092908002558000_16.9.e120335.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.02.009"},{"key":"2026092908002558000_16.9.e120335.2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308"},{"key":"2026092908002558000_16.9.e120335.3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non\u2013Small Cell Lung Cancer","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026092908002558000_16.9.e120335.4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","article-title":"Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026092908002558000_16.9.e120335.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.024"},{"key":"2026092908002558000_16.9.e120335.6","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092908002558000_16.9.e120335.7","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.iotech.2024.100808","article-title":"65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"2026092908002558000_16.9.e120335.8","doi-asserted-by":"crossref","first-page":"108883","DOI":"10.1016\/j.lungcan.2025.108883","article-title":"Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real\u2011world multicenter retrospective study","volume":"211","author":"Li","year":"2026","journal-title":"Lung Cancer"},{"key":"2026092908002558000_16.9.e120335.9","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.501","article-title":"Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non\u2010small cell lung cancer: a multi\u2010institutional retrospective cohort study","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm"},{"key":"2026092908002558000_16.9.e120335.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102394","article-title":"Enhancement of Prognostic Outcomes in Stage III Non-Small Cell Lung Cancer: A Retrospective Study on Neoadjuvant Immuno-Chemotherapy Followed by Definitive Chemo-Radiotherapy","volume":"56","author":"Ding","year":"2025","journal-title":"Transl Oncol"},{"key":"2026092908002558000_16.9.e120335.11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026092908002558000_16.9.e120335.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1591134","article-title":"Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study","volume":"16","author":"Guan","year":"2025","journal-title":"Front Immunol"},{"key":"2026092908002558000_16.9.e120335.13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijrobp.2022.12.042","article-title":"Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer","volume":"116","author":"Wang","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092908002558000_16.9.e120335.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol Cancer"},{"key":"2026092908002558000_16.9.e120335.15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"2026092908002558000_16.9.e120335.16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2022.07.015","article-title":"Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era","volume":"174","author":"McCall","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026092908002558000_16.9.e120335.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102184","article-title":"Adaptive radiation strategy with V20 limitation associates with survival benefit and lower incidence of symptomatic radiation pneumonitis in stage III NSCLC patients receiving concurrent immunotherapy and thoracic radiation","volume":"51","author":"Song","year":"2025","journal-title":"Transl Oncol"},{"key":"2026092908002558000_16.9.e120335.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-025-02639-2","article-title":"Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy","volume":"20","author":"Ma","year":"2025","journal-title":"Radiat Oncol"},{"key":"2026092908002558000_16.9.e120335.19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026092908002558000_16.9.e120335.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.011"},{"key":"2026092908002558000_16.9.e120335.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-51807-7","article-title":"Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial","volume":"15","author":"Ni","year":"2024","journal-title":"Nat Commun"},{"key":"2026092908002558000_16.9.e120335.22","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-23-0315","article-title":"Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Na\u00efve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-120335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:27Z","timestamp":1790694087000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-120335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-120335"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-120335","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}